CDKN2B甲基化.pdfVIP

research paper Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy ¨ 1 1 Michael Grovdal, Mohsen Karimi, Summary Rasheed Khan,1 Anni Aggerholm,2 Petar Antunovic,3 Jan Astermark,4 Per Bernell,5 This prospective Phase II study is the first to assess the feasibility and ¨ 6 7 efficacy of maintenance 5-azacytidine for older patients with high-risk Lena-Maria Engstrom, Lars Kjeldsen, 8 9 10 myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia and OlleLinder, LarsNilsson, AnnaOlsson, Mette S. Holm,2 Jon M. Tangen,11 Jonas MDS-acute myeloid leukaemia syndromes in complete remission (CR) after Wallvik,12 ¨ 13 Gunnar Oberg, Peter induction chemotherapy. Sixty patients were enrolled and treated by Hokland,2 Sten E. Jacobsen,9 Anna standard induction chemotherapy. Patients that reached CR started Porwit14 ¨ 1 and Eva Hellstrom-Lindberg maintenance therapy with subcutaneous azacytidine, 5/28 d until relapse. 1Division of Haematology, Department of Promoter-methylation status of CDKN2B (P15 ink4b), CDH1 and HIC1 was Medicine, Centre for Experimental Haematology, examined pre-induction, in CR and 6, 12 and 24 months post CR. Twenty- Karolinska Institutet, Karolinska University four (40%) patients achieved CR after induction chemotherapy and 23 Hospital Huddinge, Stockholm, Swede